HMGA2 Moderately Increases Fetal Hemoglobin Expression in Human Adult Erythroblasts

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2016 Nov 19

PMID 27861570

Citations 5

Authors

Jaira F de Vasconcellos

Y Terry Lee

Colleen Byrnes

Laxminath Tumburu

Antoinette Rabel

Jeffery L Miller

Affiliations

Soon will be listed here.

Abstract

Induction of fetal hemoglobin (HbF) has therapeutic importance for patients with beta-hemoglobin disorders. Previous studies showed that let-7 microRNAs (miRNAs) are highly regulated in erythroid cells during the fetal-to-adult developmental transition, and that targeting let-7 mediated the up-regulation of HbF to greater than 30% of the total globin levels in human adult cultured erythroblasts. HMGA2 is a member of the high-mobility group A family of proteins and a validated target of the let-7 family of miRNAs. Here we investigate whether expression of HMGA2 directly regulates fetal hemoglobin in adult erythroblasts. Let-7 resistant HMGA2 expression was studied after lentiviral transduction of CD34(+) cells. The transgene was regulated by the erythroid-specific gene promoter region of the human SPTA1 gene (HMGA2-OE). HMGA2-OE caused significant increases in gamma-globin mRNA expression and HbF to around 16% of the total hemoglobin levels compared to matched control transductions. Interestingly, no significant changes in KLF1, SOX6, GATA1, ZBTB7A and BCL11A mRNA levels were observed. Overall, our data suggest that expression of HMGA2, a downstream target of let-7 miRNAs, causes moderately increased gamma-globin gene and protein expression in adult human erythroblasts.

Citing Articles

let-7 miRNAs repress HIC2 to regulate BCL11A transcription and hemoglobin switching.

Huang P, Peslak S, Shehu V, Keller C, Giardine B, Shi J Blood. 2024; 143(19):1980-1991.

PMID: 38364109 PMC: 11103181. DOI: 10.1182/blood.2023023399.

Erythrocyte microRNAs: a tiny magic bullet with great potential for sickle cell disease therapy.

Verma H, Ratre Y, Bhaskar L, Colombatti R Ann Hematol. 2021; 100(3):607-614.

PMID: 33398452 DOI: 10.1007/s00277-020-04390-y.

HMGA Proteins in Hematological Malignancies.

Minervini A, Coccaro N, Anelli L, Zagaria A, Specchia G, Albano F Cancers (Basel). 2020; 12(6).

PMID: 32503270 PMC: 7353061. DOI: 10.3390/cancers12061456.

Tough decoy targeting of predominant let-7 miRNA species in adult human hematopoietic cells.

de Vasconcellos J, Byrnes C, Lee Y, Allwardt J, Kaushal M, Rabel A J Transl Med. 2017; 15(1):169.

PMID: 28768505 PMC: 5541688. DOI: 10.1186/s12967-017-1273-x.

IGF2BP1 overexpression causes fetal-like hemoglobin expression patterns in cultured human adult erythroblasts.

de Vasconcellos J, Tumburu L, Byrnes C, Lee Y, Xu P, Li M Proc Natl Acad Sci U S A. 2017; 114(28):E5664-E5672.

PMID: 28652347 PMC: 5514697. DOI: 10.1073/pnas.1609552114.

References

Narita M, Narita M, Krizhanovsky V, Nunez S, Chicas A, Hearn S . A novel role for high-mobility group a proteins in cellular senescence and heterochromatin formation. Cell. 2006; 126(3):503-14. DOI: 10.1016/j.cell.2006.05.052. View

Cavazzana-Calvo M, Payen E, Negre O, Wang G, Hehir K, Fusil F . Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature. 2010; 467(7313):318-22. PMC: 3355472. DOI: 10.1038/nature09328. View

Pleasants S . Epidemiology: a moving target. Nature. 2014; 515(7526):S2-3. DOI: 10.1038/515S2a. View

Sewchand L, Johnson C, Meiselman H . The effect of fetal hemoglobin on the sickling dynamics of SS erythrocytes. Blood Cells. 1983; 9(1):147-66. View

Lee Y, Dutta A . The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev. 2007; 21(9):1025-30. PMC: 1855228. DOI: 10.1101/gad.1540407. View

Neel J . The Inheritance of Sickle Cell Anemia. Science. 1949; 110(2846):64-6. DOI: 10.1126/science.110.2846.64. View

Tanno T, Porayette P, Sripichai O, Noh S, Byrnes C, Bhupatiraju A . Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells. Blood. 2009; 114(1):181-6. PMC: 2710947. DOI: 10.1182/blood-2008-12-195503. View

Chin M, Pellacani A, Wang H, Lin S, Jain M, Perrella M . Enhancement of serum-response factor-dependent transcription and DNA binding by the architectural transcription factor HMG-I(Y). J Biol Chem. 1998; 273(16):9755-60. DOI: 10.1074/jbc.273.16.9755. View

Piskounova E, Polytarchou C, Thornton J, LaPierre R, Pothoulakis C, Hagan J . Lin28A and Lin28B inhibit let-7 microRNA biogenesis by distinct mechanisms. Cell. 2011; 147(5):1066-79. PMC: 3227872. DOI: 10.1016/j.cell.2011.10.039. View

10.

Niwa H, Yamamura K, Miyazaki J . Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene. 1991; 108(2):193-9. DOI: 10.1016/0378-1119(91)90434-d. View

11.

Lee Y, Kim K, Byrnes C, de Vasconcellos J, Noh S, Rabel A . A synthetic model of human beta-thalassemia erythropoiesis using CD34+ cells from healthy adult donors. PLoS One. 2013; 8(7):e68307. PMC: 3704632. DOI: 10.1371/journal.pone.0068307. View

12.

CHARACHE S, Barton F, Moore R, Terrin M, Steinberg M, Dover G . Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Medicine (Baltimore). 1996; 75(6):300-26. DOI: 10.1097/00005792-199611000-00002. View

13.

Sgarra R, Rustighi A, Tessari M, Di Bernardo J, Altamura S, Fusco A . Nuclear phosphoproteins HMGA and their relationship with chromatin structure and cancer. FEBS Lett. 2004; 574(1-3):1-8. DOI: 10.1016/j.febslet.2004.08.013. View

14.

Mayr C, Hemann M, Bartel D . Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science. 2007; 315(5818):1576-9. PMC: 2556962. DOI: 10.1126/science.1137999. View

15.

Noh S, Miller S, Lee Y, Goh S, Marincola F, Stroncek D . Let-7 microRNAs are developmentally regulated in circulating human erythroid cells. J Transl Med. 2009; 7:98. PMC: 2792219. DOI: 10.1186/1479-5876-7-98. View

16.

Bauer D, Kamran S, Lessard S, Xu J, Fujiwara Y, Lin C . An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemoglobin level. Science. 2013; 342(6155):253-7. PMC: 4018826. DOI: 10.1126/science.1242088. View

17.

Noguchi C, Rodgers G, Serjeant G, Schechter A . Levels of fetal hemoglobin necessary for treatment of sickle cell disease. N Engl J Med. 1988; 318(2):96-9. DOI: 10.1056/NEJM198801143180207. View

18.

Canver M, Smith E, Sher F, Pinello L, Sanjana N, Shalem O . BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis. Nature. 2015; 527(7577):192-7. PMC: 4644101. DOI: 10.1038/nature15521. View

19.

Telen M . Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease. Blood. 2016; 127(7):810-9. PMC: 4760087. DOI: 10.1182/blood-2015-09-618553. View

20.

Rogalla P, Drechsler K, Frey G, Hennig Y, Helmke B, Bonk U . HMGI-C expression patterns in human tissues. Implications for the genesis of frequent mesenchymal tumors. Am J Pathol. 1996; 149(3):775-9. PMC: 1865134. View